1 Indications And Usage
Cosyntropin for injection is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients.
The following Structured Product Label (SPL) was submitted to the FDA by Sandoz Inc for the product Cosyntropin (NDC 0781-3440). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 important information before conducting cosyntropin for injection testing, 2.2 recommended dose for adults, 2.3 recommended dose for pediatric patients, 2.4 reconstitution instructions, 2.5 administration information, 2.6 interpretation of plasma cortisol levels after cosyntropin for injection, 3 dosage forms and strengths, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Cosyntropin for injection is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients.
Table 1. Recommended Cosyntropin for Injection Dose for Pediatric Patients
Age | Recommended Dose | Volume of Reconstituted Solution |
Birth to less than 2 years | 0.125 mg | 0.5 mL |
2 to 17 years | 0.25 mg | 1 mL |
For Injection: 0.25 mg of cosyntropin as a lyophilized powder in a single-dose vial for reconstitution.
Cosyntropin for injection is contraindicated in patients with a history of hypersensitivity to cosyntropin or to any excipients of cosyntropin for injection. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)].
Cosyntropin for injection hypersensitivity reactions including anaphylaxis have been reported. Monitor patients for hypersensitivity reactions and treat as needed.
Cortisol levels and subsequent diagnosis of adrenocortical insufficiency following cosyntropin for injection administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels.
Glucocorticoids and spironolactone may result in falsely elevated cortisol levels. Stop these drugs on the day of cosyntropin for injection testing. Long-acting glucocorticoids may need to be stopped for a longer period before cosyntropin for injection testing [see Dosage and Administration (2.1) and Drug Interactions (7)].
Estrogen-containing drugs increase cortisol binding globulin levels which can increase plasma total cortisol levels. To obtain accurate plasma total cortisol levels, stop estrogen containing drugs four to six weeks before cosyntropin for injection testing to allow cortisol binding globulin levels to return to levels within the reference range [see Dosage and Administration(2.1)and Drug Interactions (7)]. Alternatively, concomitant measurement of cortisol binding globulin at the time of testing can be done; if cortisol binding globulin levels are elevated, plasma total cortisol levels are considered inaccurate.
Any condition that elevates or lowers cortisol binding globulin levels may increase or decrease plasma total cortisol levels, respectively. Cortisol binding globulin levels can be low in cirrhosis or nephrotic syndrome. Measure cortisol binding globulin levels as necessary to ensure accuracy of interpretation of plasma total cortisol levels.
Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post approval use of cosyntropin for injection:
Risk Summary
Available data from case reports over decades of use with cosyntropin during pregnancy have not identified an increasedrisk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Unidentified adrenal insufficiency can resultin adverse maternal or fetal outcomes (see Clinical Considerations).
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk for major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Unidentified adrenal insufficiency during pregnancy can result in maternal and/or fetal death; therefore, the diagnosis of suspected adrenal insufficiency during pregnancy should not be delayed.
Risk Summary
There are no data on the presence of cosyntropin in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for cosyntropin for injection and any potential adverse effects on the breastfed infant from cosyntropin for injection or from the underlying maternal condition.
Cosyntropin for injection is approved for use in pediatric patients [see Dosage and Administration (2.3)].
Cosyntropin is an adrenocorticotropic hormone (ACTH). Cosyntropin is synthetic beta 1 - 24 corticotropin, a synthetic subunit of ACTH. It is an open chain polypeptide containing, the first 24 of the 39 amino acids of natural ACTH in sequence from N terminal. The sequence of amino acids in the 1 - 24 compound is as follows:
Molecular Formula: C136H210N40O31S
Molecular Weight: 2933 g/mol.
Cosyntropin for injection is a sterile lyophilized powder in single-dose vials containing 0.25 mg of cosyntropin and 10 mg of mannitol.
Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N-terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residues. For example, the decrement from 20 to 19 results in a 70% loss of potency.
The pharmacologic profile of cosyntropin is similar to that of purified natural ACTH. It has been established that 0.25 mg of cosyntropin will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. This dose of cosyntropin will produce maximal secretion of 17-OH corticosteroids, 17-ketosteroids and/or 17-ketogenic steroids.
Animal, human and synthetic ACTH (1-39) which all contain 39 amino acids exhibit similar immunologic activity. This activity resides in the C-terminal portion of the molecule and the 22-39 amino acid residues exhibit the greatest degree of antigenicity. In contrast, synthetic polypeptides containing 1-19 or fewer amino acids have no detectable immunologic activity. Those containing 1-26, 1-24 or 1-23 amino acids have very little immunologic although full biologic activity. This property of cosyntropin assumes added importance in view of the known antigenicity of natural ACTH.
Long-term carcinogenicity studies in animals to evaluate the carcinogenic potential of cosyntropin have not been conducted. Studies to evaluate mutagenic potential or impairment of fertility in animals have not been conducted.
How Supplied
Cosyntropin for injection 0.25 mg, in a single-dose vial for reconstitution.
Box contains 10 single-dose vials NDC 0781-3440-95
Storage and Handling
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room
Temperature].
Cosyntropin for injection is intended as a single-dose injection and contains no antimicrobial preservative. Any unused
portion should be discarded.
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information).
Hypersensitivity Reactions, Including Anaphylaxis
Inform patients and/or caregivers of the early signs of hypersensitivity reactions including rash, hives, itching, facialswelling, tightness of the chest, and wheezing [see Contraindications (4), Warnings and Precautions (5.1)].
Drug Interference with Cosyntropin for Injection Testing
Advise patients and/or caregivers to stop taking glucocorticoids and spironolactone on the day of cosyntropin for injection testing. However, for patients taking long-acting glucocorticoids, advise them to stop for longer periods before cosyntropin for injection testing. Advise patients to stop taking estrogen-containing drugs four to six weeks before cosyntropin for injection testing [seeDosage and Administration (2.1), Warnings and Precautions (5.2), and Drug Interactions (7)].
Manufactured by Oakwood Labs, for
Sandoz Inc., Princeton, NJ 08540
* Please review the disclaimer below.